Skip to main content
SpringerLink
Log in

Autologous Peripheral Blood Progenitor-Cell Transplantation versus Autologous Bone Marrow Transplantation for Adults and Children with Non-Leukaemic Malignant Disease

A Randomised Economic Study

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

A prospective economic analysis of autologous peripheral blood progenitor-cell transplantation (PBPCT) versus autologous bone marrow transplantation (BMT) was performed as part of a randomised clinical trial in 129 patients (adults and children) receiving high-dosage antineoplastic therapy for non-leukaemic malignant disease.

The clinical assessment criteria of the study were the duration of thrombocytopenia(<30 × 109/Land<50 × 109/L)and of granulocytopenia (<0.5 × 109/L).The cost of medical resources used was the primary economic end-point. We also calculated the cost of reaching 2 specified haematological end-points: platelet recovery (≥30 × 109/L) and granulocyte recovery (≥0.5 × 109/L). Economic analysis was based on the French hospital perspective.

Haematological recovery was significantly quicker in the PBPCT groups (adults and children) compared with the BMT groups. Economic study revealed that the PBPCT groups were clearly less expensive with regard to costs up to discharge (17% decrease of the average cost for adults and 29% for children) and those associated with specified haematological end-points.

The global costs of PBPCT were lower than those of BMT for these adult and paediatric populations. Economic arguments can clearly be added to clinical ones in favour of substitution of autologous PBPCT for autologous BMT. International comparisons of diffusion of PBPCT could be of great interest for further economic research into medical innovation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fox RM. Colony-stimulating factors: present status and future potential. Pharmacoeconomics 1994; 6 Suppl. 2: 1–8

    Article  PubMed  Google Scholar 

  2. Drummond MF, Menzin J, Oster G. Methodological issues in economic assessment of new therapies: the case of colony-stimulating factors. Pharmacoeconomics 1994; 6 Suppl. 2: 18–26

    Article  PubMed  Google Scholar 

  3. Faulds D, Lewis NJ, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia. Pharmacoeconomics 1992; 1: 231–49

    Article  PubMed  CAS  Google Scholar 

  4. Kumar L, Gulati SC. Peripheral stem-cell transplantation. Lancet 1995; 346 Suppl.: 9

    Article  Google Scholar 

  5. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Blood 1993; 81: 3158–63

    PubMed  CAS  Google Scholar 

  6. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–4

    Article  PubMed  CAS  Google Scholar 

  7. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor ‘mobilized’ peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–35

    PubMed  CAS  Google Scholar 

  8. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1995; 347: 353–57

    Article  Google Scholar 

  9. Gratwohl A, Hermans J. Indications and donor source of hematopoietic stem cell transplants in Europe 1993: report from the European Group for Blood and Marrow Transplantation (EBMT). Clin Transplant 1995; 9: 355–63

    PubMed  CAS  Google Scholar 

  10. Bensinger WI, Weaver CH, Appelbaum F, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85(6): 1655–58

    PubMed  CAS  Google Scholar 

  11. The European Group for Blood and Marrow Transplantation (EBMT). Hematopoietic precursor cell transplant in Europe: activity in 1994. Bone Marrow Transplant 1996; 17: 137–48

    Google Scholar 

  12. Faucher C, Le Corroller A-G, Blaise D, et al. Comparison of G-CSF primed peripheral blood progenitor and bone marrow autotransplantations: clinical assessment and cost-effectiveness study. Bone Marrow Transplant 1994; 14: 895–901

    PubMed  CAS  Google Scholar 

  13. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim): a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 30A(11): 1631–5

    Article  PubMed  CAS  Google Scholar 

  14. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AAPM, et al. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994; 30A(4): 457–9

    Article  PubMed  CAS  Google Scholar 

  15. Moatti JP, Chanut C, Benech JM. Researcher-driven versus policy-driven economic appraisal of health technologies: the case of France. Soc Sci Med 1994; 38(12): 1625–33

    Article  PubMed  CAS  Google Scholar 

  16. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. Part I. N Engl J Med 1975; 292: 832–43

    Article  PubMed  CAS  Google Scholar 

  17. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. Part II. N Engl J Med 1975; 292: 895–902

    Article  PubMed  CAS  Google Scholar 

  18. Le Corroller AG, Auquier P, Macquart-Moulin G, et al. Etude comparative des coûts monétaires et non monétaires de deux procédures de recueil des cellules souches hématopoïetiques: la cytaphérèse et le prélèvement de moelle osseuse. Rev Epidémiol Santé Publique 1996; 44: 133–43

    PubMed  Google Scholar 

  19. Journal Official de la Republique Francais, 1995: 1328–9

  20. Nomenclature Générais des actes Professionels. UCANSS ed. Paris, 1995

  21. Eisenberg JM. New drug and clinical economics: analysis of cost-effectiveness in the assessment of pharmaceutical innovations. Rev Infect Dis 1984; 6 Suppl: S905–9

    Article  PubMed  Google Scholar 

  22. Norusis N. SPSS user’s guide. Release 6.0. Chicago, 1993

  23. Pettengel R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1994; 82(12): 3770–7

    Google Scholar 

  24. Dercksen MW, Rodenhuis S, Dirkson MKA, et al. Subsets of CD34+ cells and rapid haematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995; 13(8): 1922–32

    PubMed  CAS  Google Scholar 

  25. Faucher C, Le Corroller AG, Chabannon C, et al. Autologous transplantation with G-CSF primed peripheral blood progenitor cells (PBPCT) [abstract]. Bone Marrow Transplant 1995; 15 (Suppl. 2): S34

    Google Scholar 

  26. Hartmann O, Le Corroller AG, Blaise D, et al. Clinical and economic results of a multicentric randomised trial comparing peripheral blood stem cells and bone marrow graft in autologous transplantation. Ann Intern Med. In Press

Download references

Author information

Authors and Affiliations

  1. INSERM Unit 379, Institut Paoli-Calmettes, 232 Bd Saint Marguerite, 13273, Marseille, France

    Anne-Gaëlle Le Corroller, Catherine Faucher, Didier Blaise, Cécile Fortanier & Jean-Paul Moatti

  2. Cellular Therapy and Bone Marrow Transplantation Department, Institut Paoli-Calmettes, Marseille, France

    Catherine Faucher, Didier Blaise & Dominique Maraninchi

  3. Biostatistic Department, Institut Gustave-Roussy, Villejuif, France

    Anne Auperin & Ellen Benhamou

  4. Pediatric Department, Institut Gustave-Roussy, Villejuif, France

    Olivier Hartmann

  5. Laboratoires AMGEN, Paris, France

    Jean-Charles Brosse

Authors
  1. Anne-Gaëlle Le Corroller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Auperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cécile Fortanier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ellen Benhamou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olivier Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean-Charles Brosse
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dominique Maraninchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jean-Paul Moatti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Corroller, AG., Faucher, C., Auperin, A. et al. Autologous Peripheral Blood Progenitor-Cell Transplantation versus Autologous Bone Marrow Transplantation for Adults and Children with Non-Leukaemic Malignant Disease. PharmacoEconomics 11, 454–463 (1997). https://doi.org/10.2165/00019053-199711050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00007

Keywords

Search

Navigation